|
Report No. : |
351365 |
|
Report Date : |
11.12.2015 |
IDENTIFICATION DETAILS
|
Name : |
EMCURE BRASIL FARMACEUTICA LTDA |
|
|
|
|
Registered Office : |
Rua Quintana, 950 Conj 21 - Cidade Moncões, 04569-011 - São
Paulo/SP |
|
|
|
|
Country : |
Brazil |
|
|
|
|
Date of Incorporation : |
17.01.2011 |
|
|
|
|
Legal Form : |
Limited liability company |
|
|
|
|
Line of Business : |
Trade representation of pharmaceuticals. |
|
|
|
|
No. of Employee : |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Brazil |
A2 |
A2 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
BRAZIL - ECONOMIC
OVERVIEW
Characterized by large and well-developed agricultural, mining, manufacturing, and service sectors, and a rapidly expanding middle class, Brazil's economy outweighs that of all other South American countries, and Brazil is expanding its presence in world markets. Since 2003, Brazil has steadily improved its macroeconomic stability, building up foreign reserves, and reducing its debt profile by shifting its debt burden toward real denominated and domestically held instruments. Since 2008, Brazil became a net external creditor and all three of the major ratings agencies awarded investment grade status to its debt.
After strong growth in 2007 and 2008, the onset of the global financial crisis hit Brazil in 2008. Brazil experienced two quarters of recession, as global demand for Brazil's commodity-based exports dwindled and external credit dried up. However, Brazil was one of the first emerging markets to begin a recovery. In 2010, consumer and investor confidence revived and GDP growth reached 7.5%, the highest growth rate in the past 25 years. GDP growth has slowed since 2011, due to several factors, including: overdependence on exports of raw commodities, low productivity, high operational costs, persistently high inflation, and low levels of investment. After reaching historic lows of 4.5% in early 2014, the unemployment rate remains low, but is rising. Brazil's traditionally high level of income inequality has declined for each of the last 15 years.
Brazil’s fiscal and current account balances have eroded during the past four years as the government attempted to boost economic growth through targeted tax cuts for industry and incentives to spur household consumption. After winning reelection in October 2014 by a historically narrow margin, President Dilma ROUSSEFF appointed a new economic team led by Finance Minister Joaquim LEVY, who introduced a fiscal austerity package intended to restore the primary account surplus to 1.2% of GDP and preserve the country's investment-grade sovereign credit rating.
Brazil seeks to strengthen its workforce and its economy over the long run by imposing local content and technology transfer requirements on foreign businesses, by investing in education through social programs such as Bolsa Familia and the Brazil Science Mobility Program, and by investing in research in the areas of space, nanotechnology, healthcare, and energy.
|
Source
: CIA |
EMCURE BRASIL FARMACEUTICA
LTDA
ADDRESSES
|
|
MAIN ADDRESS:
|
RUA QUINTANA, 950 CONJ 21 - CIDADE MONCÕES, |
|
ZIP CODE/CITY: |
04569-011 - SÃO PAULO/SP |
|
|
|
|
PHONE: |
11 4324-0663 |
|
E-MAIL: |
jaideep.kapoor@emcure.co.in |
|
BRANCHES: |
|
NOT AVAILABLE. |
LEGAL
DATA
|
|
MAIN
ACTIVITIES: |
|
TRADE REPRESENTATION OF PHARMACEUTICALS. |
|
LEGAL FORM: |
LIMITED
LIABILITY COMPANY |
|
|
|
|
INCORPORATION DATE: |
17/01/2011 |
|
REGISTER DATE: |
21/01/2001 |
|
BALANCE SHEET FILING DATE: |
31/12 |
|
TAX CONTRIBUTOR NUMBER(CNPJ): |
13.177.269/0001-90 |
|
STATE REGISTER: |
EXEMPT |
|
|
|
|
SHARE CAPITAL: |
R$ 20.000.000,00 |
BOARD OF DIRECTORS
|
|
|
|
|
|
JAIDEEP KAPOOR |
MANAGING PARTNER |
AUTHORIZED
USE OF SIGNATURE
|
|
THE MANAGING PARTNER IS AUTHORIZED TO
SIGN ON BEHALF OF THE COMPANY. |
|
SHAREHOLDERS
/ PARTNERS: |
|
|
|
|
|
EMCURE PHARMACEUTICALS LIMITED |
R$ 19.999.999,00 |
|
JAIDEEP KAPOOR |
R$ 1,00 |
|
AFFILIATES /
SUBSIDIARIES: |
|
|
A SCAN THROUGH OUTSIDE SOURCES SHOWED
THE SUBJECT AND/OR DIRECTORS HAS/HAVE THE FOLLOWING UNCONFIRMED HOLDINGS: |
|
|
BIOLAB EMCURE FARMACEUTICA COMERCIAL LTDA. |
|
COMPANY'S
BACKGROUND
|
|
THE SUBJECT WAS ESTABLISHED ON JANUARY
17, 2011 AS EMCURE BRASIL REPRESENTACAO COMERCIAL FARMACEUTICA LTDA. TO BE
ENGAGED IN THE SAID LINE OF BUSINESS. ON SEPTEMBER 09, 2001 IT ADOPTED THE
ABOVE-MENTIONED NAME AND UP TO DATE IT IS STILL OPERATING WITHIN THE GENERAL
SCENE REPORTED HEREIN. TRADING STYLE: EMCURE PARTNERS: EMCURE PHARMACEUTICALS LIMITED.
HEADQUARTERED AT EMCURE HOUSE,T-184,M.I.D.C,BHOSARI,PUNE - 411 026,INDIA; JAIDEEP KAPOOR, INDIANO, HOLDER OF DOCUMENTS
CPF: 235.652.558-03, RG/RNE: V8813846, RESIDENTIAL ADDRESS RUA QUINTANA, 950,
CJ.21, SAO PAULO - SP, CEP 04569-01. FURTHER DETAILS ARE SO FAR NOT KNOWN. REMARKS: -------- WHEN CONTACTING THE SUBJECT WE
INTERVIEWED MS. ALESSANDRA - ADMINISTRATIVE DEPARTMENT, WHO INFORMED THAT
WOULD NOT DISCLOSE ANY KIND OF INFORMATION. THE DATA CONTAINED HEREIN WERE OBTAINED
FROM OUTSIDE SOURCES, OUR DATABASE AND OFFICIAL. NO FURTHER DATA WAS
AVAILABLE WITH SEVERAL SOURCES USUALLY INVESTIGATED. |
PUBLIC
INFORMATION:
|
|
NO DETRIMENTAL FILES WERE FOUND. |
FINANCIAL
INFORMATION
|
|
DUE TO THE SUBJECT'S LEGAL FORM, IT IS
NOT OBLIGED TO PUBLISH THE BALANCE SHEET INFORMATION. WHEN INTERVIEWING SOURCES
AT THE SUBJECT COMPANY DECLINED TO PROVIDE ANY KIND OF FINANCIAL INFORMATION. OUR INVESTIGATION THROUGH THE OUTSIDE
SOURCES SHOWED NO FINANCIAL DATA ABOUT THE SUBJECT. |
EXCHANGE
RATE:
|
|
|
US$ 1,00 = R$ 3,79 |
- OFFICIAL RATE ON
08/12/2015 |
COMMENTS
ON THE FINANCIAL INFORMATION
|
|
IN THE ABSENCE OF FINANCIAL INFORMATION
NO COMMENTS CAN BE MADE ABOUT THE SUBJECT'S CURRENT FINANCIAL STANDING. |
REAL
ESTATE
|
NOT AVAILABLE
VEHICLES
|
NOT AVAILABLE
MACHINES
|
NOT AVAILABLE
INSURANCE
|
|
NOT AVAILABLE. |
BANKING
REFERENCES:
|
|
NOT AVAILABLE. |
|
|
|
REMARKS: IN BRAZIL THE BANKS ARE
PROHIBITED BY LAW TO PROVIDE INFORMATION OR ANY KIND OF COMMENTS ABOUT THEIR CLIENTS.
DUE TO THIS LAW PROHIBITION WE ARE UNABLE TO PROVIDE ANY BANKING DETAILS. ACCORDING TO THE CENTRAL BANK OF BRAZIL
OFFICIAL REPORT, THE COMPANY HAS NO RETURNED CHECKS UP TO DATE. (IN THE TERMS
OF "CIRCULAR 1682 BRAZILIAN CENTRAL BANK"). |
ACTIVITIES
COMMENTS
|
|
TRADE REPRESENTATION OF PHARMACEUTICALS. |
IMPORT
AND EXPORT
|
IMPORTS FROM:
|
NOT AVAILABLE. |
EXPORTS TO:
|
NOT AVAILABLE. |
MAIN
CLIENTS
|
|
|
|
|
|
|
|
DOMESTIC
CLIENTS: |
|
|
|
NOT AVAILABLE. |
|
|
STAFF
|
|
|
|
NOT AVAILABLE |
CONCEPT
AND FULFILMENT
|
|
THE SUBJECT WAS ESTABLISHED IN 2011. SO
FAR IT HAS A CLEAR TRADE HISTORY AND NO PAYMENT PROBLEM IS NOTED. LITTLE OR NOTHING IS LOCALLY KNOWN OF
SUBJECT AS A USER OF CREDIT FACILITIES DUE TO THE NATURE OF ITS ACTIVITY. |
MAIN
SUPPLIERS
|
|
|
|
|
|
|
|
DOMESTIC
SUPPLIERS: |
|
|
|
NOT AVAILABLE. |
|
|
PAYMENT
HISTORY
|
|
NO PAYMENT RECORD IS REGISTERED. |
FINAL
OPINION
|
|
BASED ON THE OVERALL DATA AVAILABLE THE SUBJECT
MAY BE CONSIDERED FOR NORMAL BUSINESS COMMITMENTS. CREDIT FACILITIES HOWEVER
SHOULD BE GRANTED ON FULLY SECURED TERMS ONLY DUE TO THE ABSENCE OF FINANCIAL
DATA. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.79 |
|
|
1 |
Rs.101.37 |
|
Euro |
1 |
Rs.73.46 |
|
BRL |
1 |
Rs.17.54 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
TRU |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.